Alnylam Pharmaceuticals, Inc.
ALNY
$292.03
$7.192.52%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 205.99M | 186.42M | 251.08M | -66.28M | -18.25M |
| Total Depreciation and Amortization | 13.55M | 13.51M | 13.80M | 13.94M | 14.41M |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 148.69M | 36.78M | 264.88M | 155.99M | 102.58M |
| Change in Net Operating Assets | -297.73M | -73.15M | -204.66M | 50.08M | -219.04M |
| Cash from Operations | 70.50M | 163.56M | 325.11M | 153.73M | -120.31M |
| Capital Expenditure | -21.83M | -23.29M | -12.14M | -14.29M | -8.97M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -3.71M | -13.87M | 513.25M | -127.09M | 122.74M |
| Cash from Investing | -25.54M | -37.17M | 501.11M | -141.38M | 113.77M |
| Total Debt Issued | -- | -680.00K | 646.37M | -- | -- |
| Total Debt Repaid | -- | -52.25M | -1.14B | -- | -- |
| Issuance of Common Stock | 13.16M | 41.70M | 77.74M | 81.22M | 49.37M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 2.56M | 56.55M | -32.08M | -27.47M | -3.28M |
| Cash from Financing | 15.71M | 45.32M | -448.35M | 53.76M | 46.08M |
| Foreign Exchange rate Adjustments | -7.06M | -5.70M | -927.00K | 27.51M | 14.06M |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 53.61M | 166.01M | 376.94M | 93.61M | 53.60M |